Aging, Frailty, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction, Physical Function, Quality of Life
Conditions
Keywords
70 and older, Inspiratory Muscle Training, Heart Failure with Preserved Ejection Fraction, Heart Failure with Reduced Ejection Fraction, Frailty, Physical function, Quality of life
Brief summary
In a randomized controlled trial, to study the utility of inspiratory muscle training (IMT) to improve functional outcomes in adults aged ≥70 years with heart failure (HF) who have been referred to palliative care for end-stage HF management. * The study team hypothesize that older HF patients will be able to use IMT safely, reliably, and effectively in a 12-week home-based training regimen. * The study team hypothesize that physical function (sit to stand, gait speed, grip strength), respiratory/pulmonary function, self-efficacy, fatigue and quality of life will increase among older HF patients randomized IMT versus those randomized to usual care.
Detailed description
Heart failure (both HF with reduced ejection fraction \[HFrEF\] and HF with preserved ejection fraction \[HFpEF\]) are on the rise in our aging population. Exercise intolerance is a leading detriment of the disease. While it is understood that exercise training is beneficial, strategies to achieve exercise training in this population are inherently limited, particularly as the issues that contribute to HF pathophysiology (i.e., advanced age, frailty, multimorbidity) also predispose to sedentariness, weakening, frailty, sarcopenia, fatigue, and cognitive impairment. Physical activity and particularly exercise training may be hard to initiate and sustain especially because it is encumbered by limitations. Home-based exercise training strategies are conceptually appealing in respect to practicality of access, but the associated issues of monitoring for effective and safe exercise, motivation, and tracking of training are all difficult to achieve in a home-based format. Furthermore, many older adults lack suitable space or resources for traditional home-based exercise training. IMT with the PrO2™ device responds to these challenges with a novel approach to achieve physiologically robust training effect (strength training of the diaphragm) in a way that mitigates breathlessness and augments multiple indices of function in a way that is practical and safe, even at home. The electronic dimensions of the device also enable embedded trackability and behavioral prompts. Overall, this is a novel approach to a common, familiar problem, and it responds directly to a well-known problem of dyspnea, sedentariness and related functional decline that undermines current standards of HF care. Existing models of exercise training for HF rely primarily on site-based regimens of aerobic and strength training modalities. Implementation barriers include unfeasible logistics for patients who often do not drive, particularly as many older patients struggle with frailty as well as limitations due to cognitive decline, sensory impairment, and/or socioeconomic challenges amidst the predictable complexities associated with advanced age. Fear and poor motivation compound these limitations, with limited options to motivate, supervise, and track progress for many candidates. This proposal promotes the concept of "Palliative Care Rehab" which is transformational in concept. It shifts the premise of cardiac rehabilitation from cardiorespiratory fitness to more rudimentary goals of activities of daily living and self-efficacy. Likewise, rather than focusing on traditional cardiovascular endpoints of exercise testing and high performance, this study is oriented to submaximal endpoints, fatigability, and qualitative metrics.
Interventions
IMT using a PrO2™ inspiratory training device will incorporate the Test of Incremental Respiratory Endurance (TIRE)9 technology to achieve an optimized exercise training regimen.
Standard of Care Participants in the usual care group will be telephoned at 4 and 8 weeks, and AE/SAE will be reviewed.
Sponsors
Study design
Masking description
Investigator, Outcomes assessor
Intervention model description
Parallel assignment
Eligibility
Inclusion criteria
* Patients with Advanced Heart Failure (HFrEF or HFpEF), with NYHA class II, III, or IV despite a minimum of * 6 weeks of treatment * Age \>70 years * Male and Female * Optimal therapy according to AHA/ACC and HFSA HF guidelines
Exclusion criteria
* Patients living in an institutional setting (e.g., skilled nursing home) during the intended period of this study. * Major cardiovascular event or procedure within the prior 6 weeks. * HF secondary to significant uncorrected primary valvular disease (except mitral regurgitation secondary to left ventricular dysfunction). If valve replacement has been performed, the participant may not be enrolled for 12 months after this procedure. * Dementia * Severe COPD (FEV1\<50%), PVD, and/or Anemia * End-stage malignancy * Severe valvular heart disease * Psychiatric hospitalization within the last 3 months * Chronic ETOH or drug dependency. We will exclude all of the following special populations: * Adults unable to consent * Individuals who are not yet adults (infants, children, teenagers) * Pregnant women * Prisoners
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Completion of 3-month Assessment | 3-month | The number of participants who complete the 3-month assessment is used as a measure of intervention feasibility. Completion of this assessment indicates the feasibility of retaining participants in the study throughout the 3-month intervention period. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in MIP (Maximum Inspiratory Pressure) | Baseline to 3-months | Change in maximum inspiratory pressure (MIP; cmH₂O). MIP is used as an indicator of inspiratory muscle strength |
| Change in Sit to Stand Time | Baseline to 3-months | Change in Sit-to-Stand Time: Time needed to complete 5 Sit-to-Stands from a chair (in seconds). |
| Change in Gait Speed | Baseline to 3-month | 4 m Gait Speed: m/sec |
| Change in the Sullivan Self-Efficacy to Maintain Function Scale | Baseline to 3-month | Change in the Sullivan Self-Efficacy to Maintain Function Scale: 0-52; higher score is more favorable |
| Change in Kansas City Cardiomyopathy Questionnaire (KCCQ): Quality of Life Score | Baseline to 3-month | Kansas City Cardiomyopathy Questionnaire (KCCQ) to measure quality of life; score: 0-100; higher is more favorable than lower score. |
| Change in Fatigue | Baseline to 3-month | Fatigue: PROMIS Item Bank v1.0 - Fatigue - short form 13a (FACIT-Fatigue): scale 0-52; lower indicates less fatigue. |
| Change in Grip Strength: kg | Baseline to 3-months | Change in Grip Strength (of dominant hand) in kilograms(kg) |
Countries
United States
Contacts
University of Pittsburgh
Participant flow
Pre-assignment details
20 individuals enrolled in the study, however, 1 participant withdrew from the study prior to assignment.
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Continuous | 74.32 Years STANDARD_DEVIATION 5.63 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 10 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 17 Participants |
| Sex: Female, Male Female | 3 Participants |
| Sex: Female, Male Male | 8 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 9 | 0 / 10 |
| other Total, other adverse events | 0 / 9 | 0 / 10 |
| serious Total, serious adverse events | 0 / 9 | 0 / 10 |